These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30288145)

  • 1. Botulinum Toxin Use in Neurourology.
    Peyronnet B; Gamé X; Vurture G; Nitti VW; Brucker BM
    Rev Urol; 2018; 20(2):84-93. PubMed ID: 30288145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of botulinum toxin A in treating neurogenic bladder.
    Weckx F; Tutolo M; De Ridder D; Van der Aa F
    Transl Androl Urol; 2016 Feb; 5(1):63-71. PubMed ID: 26904413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
    Leippold T; Reitz A; Schurch B
    Eur Urol; 2003 Aug; 44(2):165-74. PubMed ID: 12875934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
    Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
    Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).
    Mangera A; Andersson KE; Apostolidis A; Chapple C; Dasgupta P; Giannantoni A; Gravas S; Madersbacher S
    Eur Urol; 2011 Oct; 60(4):784-95. PubMed ID: 21782318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey].
    Peyronnet B; Sanson S; Amarenco G; Castel-Lacanal E; Chartier-Kastler E; Charvier K; Damphousse M; Denys P; de Seze M; Egon G; Even A; Forin V; Karsenty G; Kerdraon J; le Normand L; Loche CM; Manunta A; Mouracade P; Phe V; Previnaire JG; Ruffion A; Saussine C; Schurch B; Game X;
    Prog Urol; 2015 Dec; 25(17):1219-24. PubMed ID: 26318394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
    Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
    BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
    Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
    Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C
    J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin for the management of bladder dysfunction.
    Schurch B
    Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifications to Botulinum toxin A delivery in the management of detrusor overactivity recalcitrant to initial injections: a review.
    Doherty A; Hennessey DB; Onggo JR; Ranasinghe W; Gani J
    World J Urol; 2019 May; 37(5):891-898. PubMed ID: 30140945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of onabotulinumtoxinA on cardiac function following intradetrusor injections.
    Mehnert U; de Kort LM; Wöllner J; Kozomara M; van Koeveringe GA; Kessler TM
    Exp Neurol; 2016 Nov; 285(Pt B):167-172. PubMed ID: 27342082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.